RxDoctor Payments Data

Carl Bischoff, MD

Urology · Round Rock, TXNPI 1780756700

Payments from drug & device makers

$53,055in general payments, 2019–2025

Across 489 payments — averaging $108.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$41K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • Neotract Inc.$896
  • Urogen Pharma, Inc.$580
  • Ferring Pharmaceuticals Inc.$535
  • plus $6K from 44 others
$1,800in research payments, 2019–2025

Across 1 payment — averaging $1800.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Steris Instrument Management Services, Inc.$2K

What the payments were for

  • Speaking & faculty fees$2,4505%
  • Travel & lodging$3,1136%
  • Food & beverage$12,36923%
  • Education$35,12366%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,055 in reported general payments places this provider in the 85th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$749,120
Medicare patients
931
Services billed
10,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide83$1,169,157
OrgovyxRelugolix149$385,032
XtandiEnzalutamide23$323,393
MyrbetriqMirabegron83$79,865
GemtesaVibegron63$64,785
Abiraterone Acetate20$39,480
Mirabegron ErMirabegron32$17,228
Dutasteride214$7,517
Alfuzosin Hcl ErAlfuzosin Hcl270$5,896
Testosterone Cypionate53$2,638
Silodosin17$2,534
Tamsulosin Hcl176$2,250
Solifenacin Succinate57$2,193
Finasteride209$2,185
Cabergoline22$2,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$1,873$1,169,15783 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$463$449,817212 claims
Astellas Pharma US IncXtandi, Myrbetriq$400$403,258106 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$150$39,48020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 urology providers in Texas.

Other urology in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →